Thymosin alpha-1 vs BPC-157: immune modulation vs tissue repair, evidence-graded
Two frequently-marketed Category 2 peptides with entirely different therapeutic targets and very different evidence pedigrees.
Thymosin alpha-1 and BPC-157 share Category 2 status and both appear in biohacker 'immunity and recovery' protocols. Their evidence pedigrees are not remotely equivalent. Thymosin alpha-1 (Tα1) is approved as Zadaxin in more than 30 countries, has Phase 3 trial exposure in the US, and has a well-characterized immune-modulating mechanism. BPC-157 has essentially no Phase 3 human evidence despite hundreds of animal studies.
| Field | Thymosin alpha-1 | BPC-157 |
|---|---|---|
| Brand names | Zadaxin | Body Protection Compound |
| Manufacturer | Approved in 30+ countries (not US) | Research vendors |
| FDA approved | Approved globally; US investigational | Not approved anywhere; Category 2 (Sep 2023) |
| Indication | Chronic viral infection, cancer chemotherapy support, sepsis | Research: tissue repair, GI protection |
| Mechanism | T-cell maturation, dendritic cell activation, immune modulation | Proposed VEGF / NO / FAK pathway effects |
| Delivery | Subcutaneous injection (daily or twice-weekly) | Research-use injection |
Primary sources
- Thymosin alpha-1: Thymosin alpha-1 clinical review
Frequently asked
Which has more regulatory acceptance?
Thymosin alpha-1 by a wide margin. It's approved for specific indications in more than 30 countries (not the US). BPC-157 isn't approved anywhere.
Are they commonly combined?
In biohacker protocols targeting immune support plus injury recovery, yes. There's no clinical evidence for the combination specifically.
What's different about the 2013 sepsis trial result for thymosin alpha-1?
A Phase 3 trial in severe sepsis (PMID 24084122) reported a mortality benefit, notable because sepsis mortality reduction is rare. FDA review did not lead to US approval despite the signal — suggesting additional data needs or pathway concerns. The compound is used clinically in many other jurisdictions.